Gene Expression Profiling for Multiple Myeloma Prognosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting prognosis and identifying high-risk disease in multiple myeloma patients are inadequate, as they only account for a limited variability in outcome, and there is a need for more effective genetic markers and therapeutic targets.
Innovation Solution
Gene expression profiling identifies specific genes such as CKS1B, OPN3, and ASPM, which are overexpressed or amplified, providing a method for determining prognosis and risk, and potential therapeutic targets for multiple myeloma and other cancers, using techniques like microarray analysis and fluorescence in situ hybridization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current prognosis prediction methods are used, then the assessment is simple and quick, but the accuracy and reliability of prognosis prediction is insufficient
Solution Approach 1:
The patent segments the complex genetic analysis into specific focus on chromosome 1 abnormalities (1q gain, 1p loss, 1q amplification) rather than analyzing the entire genome. This segmentation allows for maintaining high prognosis prediction accuracy while reducing the complexity of genetic analysis by concentrating on specific chromosomal regions known to be relevant to multiple myeloma outcomes.
Solution Approach 2:
The invention applies local quality by focusing genetic analysis on specific chromosomal loci (1q and 1p regions) rather than uniform analysis across all chromosomes. This localized approach enhances prognosis prediction accuracy for multiple myeloma by concentrating resources on genetically critical regions while avoiding unnecessary complexity from analyzing unrelated genomic areas.
2Reliability
If gene expression profiling is performed on all genes, then comprehensive disease classification is achieved, but the cost and time required increases significantly
Solution Approach 1:
The patent extracts and focuses only on the essential genetic information needed for multiple myeloma prognosis - specifically chromosome 1 abnormalities - rather than performing comprehensive gene expression profiling across all genes. This extraction maintains reliable disease classification by concentrating on the most prognostically relevant genetic markers while significantly reducing the time and resources required.
Solution Approach 2:
The invention implements a dynamic approach by offering flexible profiling options that can be adapted to clinical needs - from focused analysis of specific chromosome 1 regions to more comprehensive analysis if needed. This dynamic flexibility maintains classification reliability while allowing optimization of profiling time based on individual patient requirements and clinical context.
Data Source
AI summary
Gene expression profiling in multiple myeloma patients identifies genes that distinguish between patients with subsequent early death or long survival after treatment. Poor survival is linked to over-expression of genes such as ASPM, OPN3 and CKS1B which are located in chromosome 1q. Given the frequent amplification of 1q in many cancers, it is possible that these genes can be used as powerful prognostic markers and therapeutic targets for multiple myeloma and other cancer.